<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89522-0079 </DOCNO><DOCID>fr.5-22-89.f2.A1078</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="41">[Docket No. 89M-0154]</ITAG><ITAG tagnum="56">Zimmer USA; Premarket Approval of Biological Ingrowth Anatomic Stem(BIASTM) Fiber Metal Total Hip Stem</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingits approval of the application by Zimmer USA, Warsaw, IN, for premarketapproval under the Medical Device Amendments of 1976, of the BiologicalIngrowth Anatomic Stem (BIASTM) Fiber Metal Total Hip Stem. After reviewingthe recommendation of the Orthopedic and Rehabilitation Devices Panel,FDA's Center for Devices and Radiological Health (CDRH) notified the applicant,by letter of January 31, 1989, of the approval of the application.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Petitions for administrative review by June 21, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Thomas J. Callahan, Center forDevices and Radiological Health (HFZ-410), Food and Drug Administration,8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7156.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>On June 26, 1987, Zimmer USA, Warsaw,IN 46580-0708, submitted to CDRH an application for premarket approvalof the Biological Ingrowth Anatomic Stem (BIASTM) Fiber Metal Total HipStem. The device is indicated for noncemented use in skeletally matureindividuals undergoing primary surgery for rehabilitating hips damagedas a result of noninflammatory degenerative joint disease (NIDJD) or anyof its composite diagnoses of osteoarthritis, avascular necrosis, traumaticarthritis, slipped capital epiphysis, fused hip, fracture of the pelvis,and diastropic variant. The (BIASTM) Total Hip Stem is indicated for usewith a cemented ultrahigh molecular weight polyethylene (UHMWP) acetabularcup to comprise a total hip system. Such systems consist of a femoral component,or stem, that is placed in the intramedullary canal of the femur and anacetabular component cemented in place in the pelvis. Regulatory reviewof safety and effectiveness data for the cemented use of the BIASTM TotalHip Stem is not required at this time, because use of the device with bonecement has been found to be substantially equivalent to a generic typeof device marketed in interstate commerce prior to May 28, 1976 (see 21CFR 888.3350).On January 22, 1988, the Orthopedic and Rehabilitation Devices Panel, anFDA advisory committee, reviewed and recommended approval of the application.On January 31, 1989, CDRH approved the application by a letter to the applicantfrom the Acting Director of the Office of Device Evaluation, CDRH.A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document. A copy of all approved labeling is available for public inspection at CDRH_contactThomas J. Callahan (HFZ-410), address above.<ITAG tagnum="84">Opportunity for Administrative Review</ITAG>Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) of the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b)(21 CFR 10.33(b)). A petitioner shall identify the form of review requested(hearing or independent advisory committee) and shall submit with the petitionsupporting data and information showing that there is a genuine and substantialissue of material fact for resolution through administrative review. Afterreviewing the petition, FDA will decide whether to grant or deny the petitionand will publish a notice of its decision in the <T4>Federal Register</T4>. If FDA grants the petition, the notice willstate the issue to be reviewed, the form of review to be used, the personswho may participate in the review, the time and place where the reviewwill occur, and other details.Petitioners may, at any time on or before June 21, 1989, file with theDockets Management Branch (address above) two copies of each petition andsupporting data and information, identified with the name of the deviceand the docket number found in brackets in the heading of this document.Received petitions may be seen in the office above between 9 a.m. and 4p.m., Monday through Friday.This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h)) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21">Dated: May 10, 1989.</ITAG><ITAG tagnum="6">Walter E. Gundaker,</ITAG><ITAG tagnum="4">Acting Deputy Director, Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 89-12158 Filed 5-19-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>